Bedrijfsoverzicht
Apogee Therapeutics, Inc. is a clinical stage biotechnology firm focused on the development of novel biologics designed to treat atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and various other inflammatory and immunology indications within the United States. The company operates within the healthcare sector, specifically the biotechnology industry, which is characterized by high capital intensity and a reliance on extensive research and development phases before achieving commercial product launches. With a market capitalization of $6.44B and an employee base of 261, Apogee Therapeutics holds a significant valuation relative to its current operational scale, given that its revenue figures are not publicly disclosed in the available financial data. The disparity between its substantial market cap and the absence of reported revenue indicates that the company's valuation is currently derived primarily from the potential value of its clinical pipeline and intellectual property rather than existing commercial sales. This positioning is typical for early-stage biotechnology entities where investor capital supports the transition from research to market entry, placing the company in a high-risk, high-reward segment of the healthcare market.
Financiële gezondheid
The financial statements for Apogee Therapeutics, Inc. report a Net Income (TTM) of $-255,843,008 and an EBITDA of $-284,176,992, while Revenue (TTM) is listed as N/A, reflecting the company's pre-revenue or early commercialization stage. The significant gap between reported revenue and the substantial negative net income reveals a cost structure dominated by research and development expenditures that far exceed any current revenue generation. Free Cash Flow stands at $-138,978,880, indicating that the company is consuming cash reserves to fund its operations and development programs, which limits its current financial flexibility until product approvals are secured. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that signifies the company has not yet generated sufficient gross sales to cover its direct costs and operating expenses to create a positive profit margin. On the balance sheet, the company holds $730.19M in cash against $8.85M in debt, resulting in a Debt to Equity ratio of 0.98, which suggests a leveraged position relative to equity but is mitigated by a robust cash buffer. The Current Ratio is an exceptionally high 26.57, indicating that the company possesses ample short-term assets to cover its short-term liabilities, although the composition of these assets is heavily weighted toward cash rather than liquid inventory. Return on Equity is -31.6% and Return on Assets is -21.1%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate losses rather than profits, a common characteristic for clinical-stage biotechnology firms still navigating the path to profitability.
Waarderingsbeoordeling
The valuation metrics for Apogee Therapeutics, Inc. present a trailing P/E (TTM) of N/A due to the lack of net income, while the Forward P/E is listed as -15.83, implying that the market is pricing in future earnings that are currently expected to be negative. The Price to Book ratio is 6.53, indicating that the market values the company at a significant premium over its tangible book value, a valuation multiple often seen in biotech firms where intangible assets like patents and clinical data drive value rather than physical assets. The Price to Sales ratio is N/A and the EV/EBITDA stands at -18.36, suggesting that traditional sales-based or cash-flow-based valuation multiples are not currently applicable due to the lack of positive earnings and sales data. The stock's 52-Week High is $88.35 and the 52-Week Low is $31.21; without a specific current price provided in the facts to calculate the exact percentage, the trading range demonstrates a wide volatility band of $57.14 between the high and low points. The Beta is 1.02, meaning the stock's price volatility is slightly higher than the broader market average, suggesting that the stock tends to move in tandem with the market but with a marginally amplified sensitivity to market fluctuations.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of earnings growth rates against revenue growth rates as both metrics are currently unavailable for calculation. As a non-dividend payer, the company does not distribute a Dividend Yield or maintain a Payout Ratio beyond 0.0%, meaning that any generated income is retained by the company rather than distributed to shareholders. This retention strategy implies that the company reinvests its resources, specifically the $730.19M cash on hand, directly into its clinical development programs and operational expansion to achieve future commercial milestones. The overall growth and income profile is currently defined by a reliance on retained earnings and external capital markets to fund growth, as there is no current income stream to support dividend payments or demonstrate positive historical growth rates.